Good Evening Market Enthusiast,
We are circling back to a familiar name because the story has not cooled off.
Actually, it may have gotten cleaner, louder, and a whole lot harder for the retail crowd to ignore.
This was already a past winner for our readers. Now, the latest ASCO 2026 poster adds a fresh layer to the setup: a pivotal Phase
3 trial in progress, global enrollment plan, a late-stage design targeting third-line advanced NSCLC, and a market cap still sitting in micro-cap territory.
That is the kind of mismatch momentum scanners love to sniff out before the room gets crowded.
Here is the updated Top 5 catalyst stack:
- Phase 3 Trial in Progress 🧬
The newest ASCO poster lays out a pivotal Phase 3 study comparing ateganosine sequenced with
cemiplimab against standard chemotherapy in third-line advanced NSCLC. - Primary Endpoint: Overall Survival 🎯
The study is built around OS, with secondary endpoints including ORR, PFS, DoR, DCR, and safety. - 300-Participant Global Design 🌍
The latest update is designed for approximately 300 subjects, randomized 1:1, with sites planned across the U.S., Europe, and Asia. - Prior Phase 2 Signal Still Stands Out 🔥
The selected 180 mg dose showed 17.8 months median
observed OS in advanced third-line NSCLC patients resistant to prior ICI and chemotherapy, based on the June 30, 2025 cut-off. - Sub-$100M Setup vs. $10.27 Valuation Model 👀
Recent third-party research modeled $10.27 per share, contingent on successful execution. Meanwhile, the current market cap remains roughly in the ~$80M zone based on recent share count and price math.
Tomorrow at 9:30AM ET, we break down why this Phase 3
poster may be one of the most important updates yet.
This one has science, structure, capital, and a familiar “wait… why is this still tiny?” feel.
Full reveal tomorrow.
Max Masters
Co-founder, Market Tips Newsletter
